Companies: 10,795·Total market cap: $144.5T
Arcus Biosciences, Inc.

Arcus Biosciences, Inc.

RCUSNYSEHealthcare● Active
$23.32
+$0.13(+0.56%)
Market Cap$2.3B
P/E Ratio
52W High$28.72
52W Low$7.91
Overview

Arcus Biosciences, Inc. (RCUS) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · RCUS · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-3.17rcus eps ttm · rcus earnings per shareEarnings history
PE Ratio (TTM)rcus pe ratio ttm · rcus price to earningsPE Ratio deep dive
Revenue (TTM)$236.0Mrcus revenue ttm · rcus annual revenueFull revenue history
Dividend YieldNo Dividenddoes rcus pay dividends · rcus dividend yieldDividend history
Shares Outstanding107.4Mrcus shares outstanding · rcus floatShares outstanding history
Next EarningsAug 5, 2026Est.rcus earnings date · rcus next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$247.0M▼ 4.26% YoY
202320242025
arcus biosciences, inc. revenue · rcus revenue 2025
FY 2025Net Income-$353.0M▼ 24.73% YoY
202320242025
arcus biosciences, inc. net income · rcus profit 2025
FY 2025EPS$-3.29▼ 4.78% YoY
202320242025
rcus eps · arcus biosciences, inc. earnings per share 2025
TTM:Revenue: $236.0MNet Income: -$369.0MEPS: $-3.17View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy18 analystsis rcus a buy · rcus analyst rating
Strong Buy
0
Buy
15
Hold
3
Sell
0
Strong Sell
0
12-Month Price Target
$22.00Low
$23.32Current
$31.17Avg Target33.66% upside
$47.00High
rcus price target · rcus 12 month forecast

Total: 18 · Buy rate: 83.3%

The RCUS analyst consensus is Buy, based on ratings from 18 Wall Street analysts over the past 3 months. The average 12-month price target is $31.17, representing +33.66% upside from the current price of $23.32.

Stock Performance

Full History
1D+0.56%
1W-5.28%
1M-8.04%
3M+5.47%
YTD-2.14%
1Y+136.75%
5Y-5.82%

About Arcus Biosciences, Inc.

CEOTerry J. Rosen
IPO DateMar 15, 2018
Employees627
CountryUS

Arcus Biosciences, Inc. is a U.S.-based, clinical-stage biopharmaceutical company dedicated to discovering and commercializing innovative cancer therapies. Its pipeline features several promising drug…

what is arcus biosciences, inc. · rcus stock overview · arcus biosciences, inc. company profile · who is arcus biosciences, inc. ceo · rcus NYSE · arcus biosciences, inc. headquarters · arcus biosciences, inc. business segments

About Stock Overview & Key Data

Arcus Biosciences, Inc. (RCUS) is a Healthcare company in the Biotechnology industry, listed on NYSE since Mar 15, 2018. As of the latest trading session, RCUS stock price is $23.32, with a market capitalization of $2.3B. The stock has returned +136.75% over the past 12 months and -2.14% year-to-date.

According to 18 Wall Street analysts, the consensus rating for Arcus Biosciences, Inc. stock is Buy, with an average 12-month price target of $31.17. In fiscal year 2025, Arcus Biosciences, Inc. reported revenue of $247.0M and net income of -$353.0M. For detailed data — including Arcus Biosciences, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Arcus Biosciences, Inc. (RCUS) stock price is $23.32. The stock is traded on NYSE under the ticker symbol RCUS. The 52-week range is $7.91 – $28.72.

RCUS stock priceRCUS quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice